Clinical distribution and correlation between carbapenase-resistant Pseudomonas aeruginosa and carbapenase-resistant antibacterial drugs DDDS in a tertiary hospital

PDF(1124 KB)

Journal of Microbes and Infections ›› 2024, Vol. 19 ›› Issue (2) : 88-95.

Author information +

History +

Abstract

Abstract：Objective To investigate the clinical distribution of carbapenem-resistant pseudomonas aeruginosa（CRPA）in a tertiary hospital, and the correlation ship between the CRPA detection rate and DDDS of carbapenem antibiotics, so as to provide basis for clinical treatment, prevention and control of hospital infection and rational use of antibacterial drugs. Methods Clinical strains isolated from our hospital from 2017 to 2021 were analyzed by WHONET 5.6 and SPSS 23.0 software. Results 622 pseudomonas aeruginosa (PA) were isolated from our hospital from 2017 to 2021, including 91 CRPA , with a detection rate of 14.63%. CRPA departments were mainly distributed in respiratory and critical care medicine (31.87%), Intensive Care Unit (23.08%) and neurosurgery (18.68%). Among the main specimen types, sputum and alveolar lavage fluid accounted for 81.32%, followed by wound secretion and urine, accounting for 6.59% and 5.49%, respectively. The age distribution of >80 years old (25.27%) and>60-80 years old (29.67%) was the most common. According to DDDS analysis results, the detection rate of CRPA from 2017 to 2021 was positively correlated with DDDS (R=0.82 P=0.086). In clinical departments, The detection rate of CRPA in neurosurgery was positively correlated with DDDS (R=0.78 P=0.122). Conclusion There is a positive correlation ship between CRPA isolated in our hospital and DDDS of carbapenem antibiotics. In order to avoid the occurrence of common infection and resistance of colonized bacteria, antimicrobial management should be further strengthened to promote rational clinical drug use.

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

Clinical distribution and correlation between carbapenase-resistant Pseudomonas aeruginosa and carbapenase-resistant antibacterial drugs DDDS in a tertiary hospital[J]. Journal of Microbes and Infections. 2024, 19(2): 88-95

References

[1]Hosseininassab Nodoushan SA, Yadegari S, Moghim S, etal. Distribution of the Strains of Multidrug-resistant, Extensively Drug-resistant, and Pandrug-resistant Pseudomonas aeruginosa Isolates from Burn Patients[J]. Adv Biomed Res, 2017, 27(6):74. [2]Al-Bayssari C, Valentini C, Gomez C, etal. First detection of insertion sequence element ISPa1328 in the oprD porin gene of an imipenem-resistant Pseudomonas aeruginosa isolate from an idiopathic pulmonary fibrosis patient in Marseille, France[J]. New Microbes New Infect, 2015, 14(7):26-27. [3]Release N. WHO publishes list of bacteria for which new antibiotics are urgently needed[J]. Neurosciences, 2017, 38(4):444-445. [4]Qingyi, Shi, Chen. A retrospective analysis of Pseudomonas aeruginosa bloodstream infections: prevalence, risk factors, and outcome in carbapenem-susceptible and -non susceptible infections [J]. Antimicrob Resist Infect Control, 2019, 8: 68-77. [5]Terahara F, Nishiura H. Carbapenem-resistant Pseudomonas aeruginosa and carbapenem use in Japan: an ecological study[J]. J Int Med Res, 2019, 47(10): 1-11. [6]龙彦, 武丹.近3年铜绿假单胞菌临床来源及耐药趋势探讨[J]. 中国实验诊断学,2021,25(11):1664-1666. [7]彭召红, 张娜, 张洪涛, 等. 2016—2018年某三甲医院碳青霉烯类非敏感铜绿假单胞菌的临床分布及耐药性变迁[J/OL]. 中国抗生素杂志:1-7. [8]余建洪, 李敏, 何小平, 等. 2016—2018年某医院耐碳青霉烯类铜绿假单胞菌的耐药性及临床特征分析[J]. 安徽医药,2021,25(05):931-934. [9]宋皓月, 黄凯峰, 汤荣, 等. 2014—2017年上海市某医院铜绿假单胞菌不同耐药性菌株的临床分布[J]. 中国感染控制杂志,2019,18(12):1093-1098. [10]吕红玲,邓德耀,袁文丽,等. 2015-2018年医院铜绿假单胞菌的临床分布及耐药趋势分析[J]. 中国抗生素杂志,2020,45(12):1283-1287. [11]杨怀德, 龙芳炜, 李雪梅, 等. 3927株铜绿假单胞菌感染的临床分布及耐药性变迁分析[J]. 中国处方药,2020,18(06):40-42. [12]Donlan R M. Biofilms and device-associated infections[J]. Emerg Infect Dis, 2001, 7(2): 277-281. [13]喻明洁,杨杰,熊丽蓉,等.2016-2019年铜绿假单胞菌耐药率与抗菌药物DDDs的相关性[J]. 重庆医学,2021,50(18):3102-3105 [14]夏方圆, 金瓯, 陶真, 等. 铜绿假单胞菌和鲍曼不动杆菌的耐药率与抗菌药物用药频度之间的相关性分析[J]. 中国临床药学杂志,2021,30(04):263-267. [15]王超, 郭帅, 郭佳亮, 罗敏. 铜绿假单胞菌耐药率与抗菌药物使用情况的相关性分析[J]. 中国药业,2019,28(23):78-81. [16]周芳, 王丽红, 孙晓茜, 等. 铜绿假单胞菌耐药性与抗菌药物使用强度的相关性分析[J]. 中国现代医药杂志,2020,22(03):45-48. [17]王升, 杨金兰, 胡伟, 等. 我院2014—2019年铜绿假单胞菌耐药率与抗菌药物用药频度的相关性分析[J/OL]. 中国抗生素杂志:1-8. [18]王继美, 师春焕. 住院患者铜绿假单胞菌和鲍曼不动杆菌耐药性变迁与常用抗菌药用量的相关性[J]. 药物流行病学杂志,2019,28(11):745-748. [19]高云, 王洁, 丁红梓, 等. 抗菌药物使用频度与铜绿假单胞菌耐药性的相关性[J]. 西北药学杂志,2021,36(03):504-507.